Quest Diagnostics
0
Funds holding %
of 7,398 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
100% more first-time investments, than exits
New positions opened: 118 | Existing positions closed: 59
81% more call options, than puts
Call options by funds: $63.1M | Put options by funds: $35M
5% more funds holding
Funds holding: 832 [Q3] → 872 (+40) [Q4]
3% more repeat investments, than reductions
Existing positions increased: 303 | Existing positions reduced: 295
0.55% more ownership
Funds ownership: 87.92% [Q3] → 88.46% (+0.55%) [Q4]
1% less capital invested
Capital invested by funds: $15.1B [Q3] → $14.9B (-$219M) [Q4]
50% less funds holding in top 10
Funds holding in top 10: 2 [Q3] → 1 (-1) [Q4]
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$170
1%
upside
Avg. target
$179
6%
upside
High target
$191
13%
upside
9 analyst ratings
3 positive
33%
6 neutral
67%
0 negative
0%
Baird Eric Coldwell 42% 1-year accuracy 14 / 33 met price target | 13%upside $191 | Outperform Maintained | 20 Mar 2025 |
Citigroup Patrick Donnelly 23% 1-year accuracy 7 / 31 met price target | 9%upside $185 | Neutral Downgraded | 4 Mar 2025 |
JP Morgan Lisa Gill 74% 1-year accuracy 17 / 23 met price target | 7%upside $180 | Neutral Maintained | 4 Feb 2025 |
Mizuho Ann Hynes 67% 1-year accuracy 10 / 15 met price target | 5%upside $178 | Outperform Maintained | 3 Feb 2025 |
UBS Kevin Caliendo 50% 1-year accuracy 7 / 14 met price target | 1%upside $170 | Neutral Maintained | 3 Feb 2025 |
Financial journalist opinion
Based on 6 articles about DGX published over the past 30 days
Positive
Zacks Investment Research
5 days ago
Is Quest Diagnostics Stock Worth Holding Onto Right Now?
Strong momentum in Advanced Diagnostics and strategic acquisitions continues to attract investors to DGX.
Positive
Zacks Investment Research
1 week ago
DGX Stock Set to Benefit From New Google Cloud Partnership
Quest Diagnostics teams up with Google Cloud to streamline data and personalize customer experiences using gen AI.
Positive
Zacks Investment Research
1 week ago
Tap Billion-Dollar AI Opportunity in Oncology: Stocks in the Spotlight
Betting on AI-driven precision oncology companies presents a compelling long-term opportunity for investors. Some of the stocks in focus are BTAI, TEM and DGX.
Neutral
PRNewsWire
1 week ago
Quest Diagnostics to Highlight Strategic Priorities to Drive Sustainable Growth and Deliver Long-term Shareholder Value at 2025 Investor Day
Provides long-term outlook beyond 2025: Revenues expected to grow at 4-5% compound annual growth rate (CAGR); adjusted diluted earnings per share (EPS) expected to grow at 7-9% CAGR Reaffirms guidance for full year 2025 SECAUCUS, N.J. , March 19, 2025 /PRNewswire/ -- At a meeting with analysts and investors at its 2025 Investor Day, members of the leadership team of Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will discuss the company's strategies to drive sustainable growth and deliver long-term shareholder value.
Neutral
PRNewsWire
2 weeks ago
Quest Diagnostics to Collaborate with Google Cloud to Streamline Data and Personalize Customer Experiences Using Generative AI
SUNNYVALE, Calif. and SECAUCUS, N.J.
Positive
Zacks Investment Research
4 weeks ago
Quest Diagnostics Stock Jumps 38% in a Year: What's Behind the Surge?
DGX outperforms the industry and the S&P 500 composite's gain in the past year, driven by strong core performance and contributions from acquisitions.
Positive
Zacks Investment Research
1 month ago
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
DGX stays on investors' radars due to its robust prospects in Advanced Diagnostics and progress in the acquisition strategy.
Neutral
PRNewsWire
1 month ago
Fresenius Medical Care Announces Divestment of Select Laboratory Assets to Quest Diagnostics
Quest to provide comprehensive dialysis-related laboratory and water testing services to Fresenius Medical Care owned and affiliated clinics in the United States BAD HOMBURG, Germany and SECAUCUS, N.J. , Feb. 24, 2025 /PRNewswire/ -- Fresenius Medical Care (XETRA: FME; NYSE: FMS), the world's leading provider of products and services for individuals with renal disease, and Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, today announced that, under terms of a definitive acquisition agreement, Quest will acquire select assets of FME's wholly owned Spectra Laboratories, a leading provider of renal-specific laboratory testing services in the U.S. In addition, under a separate agreement, Quest will provide comprehensive laboratory services related to end-stage kidney disease (ESKD) and specialized water testing for patients and providers served by dialysis centers operated by Fresenius Medical Care and its wholly owned and joint-venture partners in the United States.
Neutral
PRNewsWire
1 month ago
Quest Diagnostics to Host Investor Day on March 19, 2025
SECAUCUS, N.J. , Feb. 13, 2025 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leading provider of diagnostic information services, will host an Investor Day for institutional investors and financial analysts in New York City on Thursday, March 19, 2025 at the New York Stock Exchange.
Neutral
PRNewsWire
1 month ago
GRAIL and Quest Diagnostics Provide GRAIL's Galleri® Multi-Cancer Early Detection (MCED) Test Through the Quest Diagnostics Test Ordering System
GRAIL's Galleri Test Now Directly Available to Physicians in the U.S. Through Collaboration With Quest Diagnostics, Delivering a More Streamlined Provider and Patient Experience MENLO PARK, Calif. and SECAUCUS, N.J.
Charts implemented using Lightweight Charts™